Literature DB >> 6129979

Within patient comparison of prazosin and UK-33,274. A new alpha-adrenoceptor-antagonist.

P W de Leeuw, J J Ligthart, A J Smout, W H Birkenhäger.   

Abstract

Eleven patients with uncomplicated essential hypertension received increasing single daily doses of UK-33,274, a new alpha-1 adrenoceptor antagonist, and prazosin for 4 days, in a open cross-over study. Doses were increased until a satisfactory blood pressure response was obtained. Average doses reached were 4.5 mg for UK-33,274 and 2.4 mg for prazosin. The maximum effect of the two drugs on standing blood pressure was similar, but prazosin was more effective in the supine position. Both drugs had a greater effect on standing than on supine blood pressure. UK-33,274 caused a consistent increase in heart rate while prazosin did not. Whereas there was no clear difference between the two compounds in the duration of the reduction in blood pressure the onset of action was more gradual for UK-33,274. The incidence of side-effects was similar for both drugs. The data suggest that UK-33,274 is less effective than prazosin in reducing blood pressure.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6129979     DOI: 10.1007/bf00605988

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

Review 1.  Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-09       Impact factor: 9.546

2.  The use of non-parametric methods in the statistical analysis of the two-period change-over design.

Authors:  G G Koch
Journal:  Biometrics       Date:  1972-06       Impact factor: 2.571

3.  Postjunctional selectivity of alpha-blockade with prazosin, trimazosin, and UK-33,274 in man.

Authors:  W Singleton; C A Saxton; J Hernandez; B N Prichard
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

4.  Effects of prazosin on autonomic control of circulation in essential hypertension.

Authors:  G Mancia; A Ferrari; L Gregorini; M C Ferrari; C Bianchini; L Terzoli; G Leonetti; A Zanchettie
Journal:  Hypertension       Date:  1980 Sep-Oct       Impact factor: 10.190

  4 in total
  5 in total

Review 1.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

2.  Doxazosin versus nitrendipine: a double-blind comparative study in patients adhering to a sodium-restricted diet.

Authors:  A Cosenzi; F L Waltman; P N van Es; P W de Leeuw
Journal:  Cardiovasc Drugs Ther       Date:  1994-06       Impact factor: 3.727

3.  A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension.

Authors:  M H Frick; P Halttunen; P Himanen; M Huttunen; P Pörsti; T Pitkäjärvi; L Pöyhönen; M L Pyykönen; P Reinikainen; P Salmela
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

4.  Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise.

Authors:  P Lund-Johansen; P Omvik; H Haugland
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 5.  Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.

Authors:  R A Young; R N Brogden
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.